WO2001062252A1 - Tyrosine kinase inhibitors - Google Patents
Tyrosine kinase inhibitors Download PDFInfo
- Publication number
- WO2001062252A1 WO2001062252A1 PCT/US2001/005567 US0105567W WO0162252A1 WO 2001062252 A1 WO2001062252 A1 WO 2001062252A1 US 0105567 W US0105567 W US 0105567W WO 0162252 A1 WO0162252 A1 WO 0162252A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- substituents selected
- alkyl
- compound
- inhibitor
- Prior art date
Links
- 0 *C(C1=**=*)=CNC1=* Chemical compound *C(C1=**=*)=CNC1=* 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
- tyrosine kinase-dependent diseases and conditions such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
- Tyrosine kinases are a class of enzymes that catalyze the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. Tyrosine kinases are believed, by way of substrate phosphorylation, to play critical roles in signal transduction for a number of cell functions. Though the exact mechanisms of signal transduction is still unclear, tyrosine kinases have been shown to be important contributing factors in cell proliferation, carcinogenesis and cell differentiation.
- Tyrosine kinases can be categorized as receptor type or non-receptor type.
- Receptor type tyrosine kinases have an extracellular, a transmembrane, and an intracellular portion, while non-receptor type tyrosine kinases are wholly intracellular.
- the receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about 20 different subfamilies of receptor-type tyrosine kinases have been identified.
- One tyrosine kinase subfamily, designated the HER subfamily is comprised of EGFR, HER2, HER3, and HER4.
- Ligands of this subfamily of receptors include epithileal growth factor, TGF- , amphiregulin, HB-EGF, betacellulin and heregulin.
- TGF- epithileal growth factor
- amphiregulin amphiregulin
- HB-EGF betacellulin
- heregulin Another subfamily of these receptor-type tyrosine kinases is the insulin subfamily, which includes INS-R, IGF-IR, and IR-R.
- the PDGF subfamily includes the PDGF- ⁇ and ⁇ receptors, CSFIR, c-kit and FLK-II.
- the FLK family which is comprised of the kinase insert domain receptor (KDR), fetal liver kinase- 1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (flt-1).
- KDR kinase insert domain receptor
- FLK-1 fetal liver kinase- 1
- FLK-4 fetal liver kinase-4
- flt-1 fms-like tyrosine kinase-1
- the non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack, and LIMK. Each of these subfamilies is further sub-divided into varying receptors.
- the Src subfamily is one of the largest and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr, and Yrk.
- the Src subfamily of enzymes has been linked to oncogenesis.
- Both receptor-type and non-receptor type tyrosine kinases are implicated in cellular signaling pathways leading to numerous pathogenic conditions, including cancer, psoriasis and hyperimmune responses.
- receptor-type tyrosine kinases and the growth factors that bind thereto, have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, J. Cell Biol. 129:895-898, 1995).
- One such receptor-type tyrsoine kinase is fetal liver kinase 1 or FLK-1.
- FLK- 1 The human analog of FLK- 1 is the kinase insert domain-containing receptor KDR, which is also known as vascular endothelial cell growth factor receptor 2 or VEGFR-2, since it binds VEGF with high affinity.
- VEGF and KDR are a ligand-receptor pair that play an important role in the proliferation of vascular endo- thelial cells, and the formation and sprouting of blood vessels, termed vasculogenesis and angiogenesis, respectively.
- VEGF vascular endothelial growth factor
- KDR mediates the mitogenic function of VEGF whereas Flt-1 appears to modulate non- mitogenic functions such as those associated with cellular adhesion. Inhibiting KDR thus modulates the level of mitogenic VEGF activity.
- tumor growth has been shown to be susceptible to the antiangiogenic effects of VEGF receptor antagonists. (Kim et al., Nature 362, pp. 841-844, 1993). Solid tumors can therefore be treated by tyrosine kinase inhibitors since these tumors depend on angiogenesis for the formation of the blood vessels necessary to support their growth.
- These solid tumors include histiocytic lymphoma, cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung, including lung adenocarcinoma and small cell lung cancer. Additional examples include cancers in which overexpression or activation of Raf-activating oncogenes (e.g., K-ras, erb-B) is observed. Such cancers include pancreatic and breast carcinoma. Accordingly, inhibitors of these tyrosine kinases are useful for the prevention and treatment of prolif erative diseases dependent on these enzymes.
- the angiogenic activity of VEGF is not limited to tumors.
- VEGF accounts for most of the angiogenic activity produced in or near the retina in diabetic retinopathy. This vascular growth in the retina leads to visual degeneration culminating in blindness. Ocular VEGF mRNA and protein are elevated by conditions such as retinal vein occlusion in primates and decreased ⁇ 2 levels in mice that lead to neovascularization. Intraocular injections of anti- VEGF monoclonal antibodies or VEGF receptor immunofusions inhibit ocular neovascularization in both primate and rodent models. Regardless of the cause of induction of VEGF in human diabetic retinopathy, inhibition of ocular VEGF is useful in treating the disease.
- VEGF vascular endothelial growth factor
- oncogenes ras, raf, src and mutant p53 all of which are relevant to targeting cancer.
- Monoclonal anti- VEGF antibodies inhibit the growth of human tumors in nude mice. Although these same tumor cells continue to express VEGF in culture, the antibodies do not diminish their mitotic rate. Thus tumor- derived VEGF does not function as an autocrine mitogenic factor. Therefore, VEGF contributes to tumor growth in vivo by promoting angiogenesis through its paracrine vascular endothelial cell chemotactic and mitogenic activities.
- These monoclonal antibodies also inhibit the growth of typically less well vascularized human colon cancers in athymic mice and decrease the number of tumors arising from inoculated cells.
- VEGF-binding construct of Flk-1, Flt-1, the mouse KDR receptor homologue truncated to eliminate the cytoplasmic tyrosine kinase domains but retaining a membrane anchor, virtually abolishes the growth of a transplantable glioblastoma in mice presumably by the dominant negative mechanism of heterodimer formation with membrane spanning endothelial cell VEGF receptors.
- Embryonic stem cells which normally grow as solid tumors in nude mice, do not produce detectable tumors if both VEGF alleles are knocked out. Taken together, these data indicate the role of VEGF in the growth of solid tumors.
- KDR or Flt-1 are implicated in pathological angiogenesis, and these receptors are useful in the treatment of diseases in which angiogenesis is part of the overall pathology, e.g., inflammation, diabetic retinal vascularization, as well as various forms of cancer since tumor growth is known to be dependent on angiogenesis.
- the present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases.
- One embodiment of the present invention is illustrated by a compound of Formula I , and the pharmaceutically acceptable salts and stereoisomers thereof:
- the compounds of this invention are useful in the inhibition of kinases and are illustrated by a compound of Formula I :
- Rl, Rla R4 and R5 are independently selected from:
- R2 and R3 are independently selected from the group consisting of:
- aryl said alkyl, aryl, alkenyl and alkynyl is optionally substituted with one to three substituents selected from R6;
- R4a is selected from the group consisting of:
- alkyl, aryl, alkenyl and alkynyl is optionally substituted with one to three substituents selected from R6;
- R6 is:
- R ⁇ a is:
- R8 are independently selected from:
- R7 and R8 can be taken together with the nitrogen to which they are attached to form a 5-7 membered heterocycle containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one to three substituents selected from R° ⁇
- Rl, R la , R4 and R5 are independently selected from: 1) H,
- R4a i s (C O)O a C ⁇ -C6 alkyl or C1-C6 alkyl;
- R6 is:
- R ⁇ a is: 1) H,
- R8 are independently selected from:
- R7 and R can be taken together with the nitrogen to which they are attached to form a 5-7 membered heterocycle containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one to three substituents selected from R6a.
- Rl and R are independently selected from:
- R2 and R are independently selected from H and methyl
- R4a is methyl
- R5 and Rla are H
- R6 is: 1) H
- R6a is:
- R7 and R are independently selected from:
- Ci-Cio alkyl optionally substituted with one to three substituents selected from R6a, 5) aryl, optionally substituted with one to three substituents selected from
- R7 and R8 can be taken together with the nitrogen to which they are attached to form a piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group, optionally substituted with one or two substituents selected from R° ⁇
- Yet another embodiment of the present invention is a compound which is 3-(4-methyl-5-oxo-4,5-dihydro-lH-pyrrolo[3,2-b]pyridin-2-yl)-lH-quinolin-2-one or a pharmaceutically acceptable salt or stereoisomer thereof.
- a pharmaceutical composition which is comprised of a compound of Formula I as described above and a pharmaceutically acceptable carrier.
- the present invention also encompasses a method of treating or preventing cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of Formula I.
- Preferred cancers for treatment are selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.
- Another set of preferred forms of cancer are histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, gioblastomas and breast carcinoma.
- a method of treating or preventing a disease in which angiogenesis is implicated which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I.
- a disease in which angiogenesis is implicated is ocular diseases such as retinal vascularization, diabetic retinopathy, age-related macular degeneration, and the like.
- Also included within the scope of the present invention is a method of treating or preventing inflammatory diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I.
- inflammatory diseases are rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reactions, and the like.
- Also included is a method of treating or preventing a tyrosine kinase- dependent disease or condition in a mammal which comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
- the therapeutic amount varies according to the specific disease and is discernable to the skilled artisan without undue experimentation.
- a method of treating or preventing retinal vascularization which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of compound of Formula I is also encompassed by the present invention.
- Methods of treating or preventing ocular diseases such as diabetic retinopathy and age-related macular degeneration, are also part of the invention.
- Also included within the scope of the present invention is a method of treating or preventing inflammatory diseases, such as rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions, as well as treatment or prevention of bone associated pathologies selected from osteosarcoma, osteoarthritis, and rickets.
- the invention also contemplates the use of the instantly claimed compounds in combination with a second compound selected from:
- Preferred angiogenesis inhibitors are selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP (matrix metalloprotease) inhibitor, an integrin blocker, interferon- ⁇ , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)- fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.
- Preferred estrogen receptor modulators are tamoxifen and raloxifene.
- a method of treating cancer which comprises administering a therapeutically effective amount of a compound of Formula I in combination with radiation therapy and/or in combination with a compound selected from:
- Yet another embodiment of the invention is a method of treating cancer which comprises administering a therapeutically effective amount of a compound of Formula I in combination with paclitaxel or trastuzumab.
- Also within the scope of the invention is a method of reducing or preventing tissue damage following a cerebral ischemic event which comprises administering a therapeutically effective amount of a compound of Formula I.
- Another embodiment of the invention is a method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Formula I in combination with a COX-2 inhibitor.
- Tyrosine kinase-dependent diseases or conditions refers to pathologic conditions that depend on the activity of one or more tyrosine kinases. Tyrosine kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion and migration, and differentiation. Diseases associated with tyrosine kinase activities include the proliferation of tumor cells, the pathologic neovascularization that supports solid tumor growth, ocular neovascularization (diabetic retinopathy, age- related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like).
- the compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E.L. Eliel and S.H. Wilen, Stereochemistry of Carbon Compounds, John Wiley & Sons, New York, 1994, pages 1119- 1190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, being included in the present invention.
- the compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. For example, any claim to compound A below is understood to include tautomeric structure B, and vice versa, as well as mixtures thereof.
- any variable e.g. aryl, heterocycle, Rl, R2 etc.
- its definition on each occurrence is independent at every other occurrence.
- combinations of substituents and variables are permissible only if such combinations result in stable compounds.
- Lines drawn into the ring systems from substituents indicate that the indicated bond may be attached to any of the substitutable ring carbon atoms. If the ring system is polycyclic, it is intended that the bond be attached to any of the suitable carbon atoms on the proximal ring only.
- X and Z are C
- R5 is CH3
- R3 is H
- substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials.
- alkyl is intended to include both branched, straight- chain, and cyclic saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- Ci-Cio as in “Ci-Cio alkyl” is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear, branched, or cyclic arrangement.
- Ci-Cio alkyl specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and so on, as well as cycloalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydro- naphthalene, methylenecylohexyl, and so on.
- Alkoxy represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge.
- alkenyl refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to 4 non-aromatic carbon-carbon double bonds may be present.
- C2-C6 alkenyl means an alkenyl radical having from 2 to 6 carbon atoms.
- Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
- alkynyl refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond. Up to 3 carbon-carbon triple bonds may be present.
- C2-C6 alkynyl means an alkynyl radical having from 2 to 6 carbon atoms.
- Alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
- aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 atoms in each ring, wherein at least one ring is aromatic.
- aryl elements include phenyl, naphthyl, tetrahydro- naphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
- the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
- heteroaryl represents a stable monocyclic or bicyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S.
- Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrahydroquinoline.
- the heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively.
- halo or halogen as used herein is intended to include chloro, fluoro, bromo and iodo.
- heterocycle or “heterocyclyl” as used herein is intended to mean a 5- to 10-membered aromatic or nonaromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S, and includes bicyclic groups. "Heterocyclyl” therefore includes the above mentioned heteroaryls, as well as dihydro and tetrathydro analogs thereof.
- heterocyclyl include, but are not limited to the following: benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridazinyl
- the pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
- R7 and R are defined such that they can be taken together with the nitrogen to which they are attached to form a 5-7 membered heterocycle containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one to three substituents selected from R6a
- 5-7 membered ring systems that can thus be formed include, but are not limited to the following:
- Rl is H, Ci-C ⁇ alkyl, or aryl. Most preferably Rl is H or C1-C6 alkyl.
- Rla The preferred definition of Rla is H.
- R4 is OH, OC1-C6 alkyl, C1-C6 alkyl.
- R4a i s C1-C6 alkyl.
- R5 is H or C1-C6 alkyl. Most preferably R5 is H.
- the pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic or acidic moiety by conventional chemical methods.
- the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt- orming inorganic or organic acid in a suitable solvent or various combinations of solvents.
- the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.
- the compounds of this invention may be prepared by employing reactions as shown in the following schemes, in addition to other standard manipulations that are known in the literature or exemplified in the experimental procedures. These schemes, therefore, are not limited by the compounds listed nor by any particular substituents employed for illustrative purposes. Substituent numbering as shown in the schemes does not necessarily correlate to that used in the claims.
- the quinoline reagent 1-2 can be synthesized by the general procedures taught in Marsais, F; Godard, A.; Queguiner, G. J. Hetero- cyclic Chem. 1989, 26, 1589-1594). Derivatives with varying substitution can be made by modifying this procedure and use of standard synthetic protocols known in the art.
- Intermediate 1-2 is then coupled with the appropriate N-protected pyrollo- compound, structure 1-4, to produce a chlorinated intermediate of structure 1-5. At least one of the R4 substituents would be OH or OR on the carbon adjacent to the ring nitrogen. Heating of 1-5 in aqueous acetic acid produces the desired de-chlorinated product, 1-6.
- Scheme 2 shows an example using this route to arrive at a [3,2]- pyridno-pyrole, 2-3.
- the ⁇ -alkyloxy pyridino-pyroles 3-1 can be converted to the corresponding pyrimidinone analogs 3-2 by heating with aqueous HBr.
- the pyrimidinone analogs can be synthesized via the N-oxide intermediates 4-2 as shown in Scheme 4.
- Scheme 5 shows the N-alkylation of the pyrimidinone-pyrole 3-2 to arrive at the compounds of Formula I.
- Other electrophilic reagents can be employed to alkylate or acylate the nitrogen, as will be apparent to the skilled artisan.
- step 1 t-BuLi
- the instant compounds are useful as pharmaceutical agents for mammals, especially for humans, in the treatment of tyrosine kinase dependent diseases.
- diseases include the proliferation of tumor cells, the pathologic neovascularization (or angiogenesis) that supports solid tumor growth, ocular neovascularization (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like).
- the compounds of the instant invention may be administered to patients for use in the treatment of cancer.
- the instant compounds inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. Cancer Research, 55:4575-4580, 1995).
- the anti-angiogenesis properties of the instant compounds are also useful in the treatment of certain forms of blindness related to retinal vascularization.
- the disclosed compounds are also useful in the treatment of certain bone-related pathologies, such as osteosarcoma, osteoarthritis, and rickets, also known as oncogenic osteomalacia.
- bone-related pathologies such as osteosarcoma, osteoarthritis, and rickets
- oncogenic osteomalacia also known as oncogenic osteomalacia.
- VEGF directly promotes osteoclastic bone resorption through KDR/Flk-1 expressed in mature osteoclasts (FEBS Let.
- the instant compounds are also useful to treat and prevent conditions related to bone resorption, such as osteoporosis and Paget's disease.
- the claimed compounds can also be used to reduce or prevent tissue damage which occurs after cerebral ischemic events, such as stroke, by reducing cerebral edema, tissue damage, and reperfusion injury following ischemia. (Drug News Perspect 11:265-270 (1998); /. Clin. Invest. 104:1613-1620 (1999)).
- the compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice.
- the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
- the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
- carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added.
- useful diluents include lactose and dried corn starch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.
- sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered.
- the total concentration of solutes should be controlled in order to render the preparation isotonic.
- the compounds of the instant invention may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.
- combinations that would be useful include those with antiresorptive bisphosphonates, such as alendronate and risedronate; integrin blockers (defined further below), such as oc v ⁇ 3 antagonists; conjugated estrogens used in hormone replacement therapy, such as PREMPRO®, PREMARTN® and ENDOMETRION®; selective estrogen receptor modulators (SERMs), such as raloxifene, droloxifene, CP-336,156 (Pfizer) and lasofoxifene; cathespin K inhibitors; and ATP proton pump inhibitors.
- SERMs selective estrogen receptor modulators
- the instant compounds are also useful in combination with known anti-cancer agents.
- known anti-cancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-
- CoA reductase inhibitors HJV protease inhibitors, reverse transcriptase inhibitors, and other angiogenesis inhibitors.
- the instant compounds are particularly useful when coadminsitered with radiation therapy.
- the synergistic effects of inhibiting VEGF in combination with radiation therapy have been described in the art. (see WO 00/61186).
- Estrogen receptor modulators refers to compounds which interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism.
- Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY117081 , toremifene, fulvestrant, 4-[7-(2,2-dimethyl-l- oxopropoxy-4-methyl-2-[4-[2-(l-piperidinyl)ethoxy]phenyl]-2H-l-benzopyran-3-yl]- phenyl-2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl- hydrazone, and SH646.
- Androgen receptor modulators refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism.
- Examples of androgen receptor modulators include finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.
- Retinoid receptor modulators refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism.
- retinoid receptor modulators examples include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, ⁇ -difluoromethylornithine, ILX23-7553, trans-N-(4'- hydroxyphenyl) retinamide, N-4-carboxyphenyl retinamide, "Cytotoxic agents” refer to compounds which cause cell death primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, microtubulin inhibitors, and topoisomerase inhibitors.
- cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl- pyridine) platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)- bis-mu-(hexane- 1 ,6-
- microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3 ,4,5 ,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl- L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, and BMS188797.
- topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo-benzylidene- chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2- (6H)propanamine, l-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl- lH,12H-benzo[de]pyrano[3',4':b,7]indolizino[l,2b]quinoline-10,13(9H,15H) dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPIllOO, BN80915, BN80942, etoposide phosphat
- Antiproliferative agents includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 , and INX3001 , and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fmdarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methy ⁇ idenecytidine, 2'-fluoromethylene-2'- deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N'-(3,4-
- Antiproliferative agents also includes monoclonal antibodies to growth factors, other than those listed under “angiogenesis inhibitors”, such as trastuzumab, and tumor suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Patent No. 6,069,134, for example).
- HMG-CoA reductase inhibitors refers to inhibitors of 3-hydroxy- 3-methylglutaryl-CoA reductase.
- Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Patent 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33.
- the terms "HMG-CoA reductase inhibitor” and “inhibitor of HMG-CoA reductase” have the same meaning when used herein.
- HMG-CoA reductase inhibitors examples include but are not limited to lovastatin (MEVACOR®; see US Patent No. 4,231,938;
- HMG- CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention.
- An illustration of the lactone portion and its corresponding open-acid form is shown below as structures I and ⁇ .
- HMG-CoA reductase inhibitors where an open-acid form can exist
- salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term "HMG-CoA reductase inhibitor" as used herein.
- the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin.
- the term "pharmaceutically acceptable salts" with respect to the HMG-CoA reductase inhibitor shall mean non- toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, l-p-chlorobenzyl-2-pyrrolidine- -yl-methylbenz- imidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane.
- a suitable organic or inorganic base particularly those formed from cations
- salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamao
- Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
- Prenyl-protein transferase inhibitor refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-IJ (GGPTase-II, also called Rab GGPTase).
- FPTase farnesyl-protein transferase
- GGPTase-I geranylgeranyl-protein transferase type I
- GGPTase-II geranylgeranyl-protein transferase type-IJ
- prenyl-protein transferase inhibiting compounds examples include ( ⁇ )-6-[amino(4-chlorophenyl)(l-methyl-lH-imidazol-5- yl)methyl]-4-(3-chlorophenyl)-l-methyl-2(lH)-quinolinone, (-)-6-[amino(4- chlorophenyl) ( 1 -methyl- 1 ⁇ -imidazol-5-yl)methyl] -4-(3 -chlorophenyl)- 1 -methyl- 2(lH)-quinolinone, (+)-6-[amino(4-chlorophenyl)(l-methyl-l ⁇ -imidazol-5- yl)methyl]-4-(3-chlorophenyl)-l-methyl-2(lH)-quinolinone, 5(S)-n-butyl-l-(2,3- dimethylphenyl)-4-[l-(4-cyanobenzyl)-5
- prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U. S. Patent No. 5,420,245, U. S. Patent No. 5,523,430, U. S. Patent No. 5,532,359, U. S. Patent No. 5,510,510, U. S. Patent No. 5,589,485, U. S. Patent No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ.
- HTV protease inhibitors examples include amprenavir, abacavir, CGP-73547, CGP-61755, DMP-450, indinavir, nelfinavir, tipranavir, ritonavir, saquinavir, ABT-378, AG 1776, and BMS-232,632.
- reverse transcriptase inhibitors include delaviridine, efavirenz, GS-840, HB Y097, lamivudine, nevirapine, AZT, 3TC, ddC, and ddl.
- Angiogenesis inhibitors refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism.
- angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR20), inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- ⁇ , interleukin- 12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti- inflammatories (NS AIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib and rofecoxib (PNAS, Vol.
- tyrosine kinase inhibitors such as inhibitors of the tyrosine
- NSAID's which are potent COX-2 inhibiting agents.
- an NSAID is potent if it possess an IC50 for the inhibition of COX-2 of l ⁇ M or less as measured by the cell or microsomal assay disclosed herein.
- NSAID's which are selective COX-2 inhibitors are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC50 for COX-2 over IC50 for COX-1 evaluated by the cell or rnicromsal assay disclosed hereinunder.
- Such compounds include, but are not limited to those disclosed in U.S. 5,474,995, issued December 12, 1995, U.S. 5,861,419, issued January 19, 1999, U.S. 6,001,843, issued December 14, 1999, U.S. 6,020,343, issued February 1, 2000, U.S.
- inhibitors of COX-2 include the following: 3-(3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone;
- Inhibitors of COX-2 that are particularly useful in the instant method of treatment are:
- angiogenesis inhibitors include, but are not limited to, endostation, ukrain, ranpirnase, EVI862, 5-methoxy-4-[2-methyl-3-(3-methyl-2- butenyl)oxiranyl]-l-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-l-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-lH-l,2,3-triazole-4- carboxamide,CM101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7 ,7-(carbonyl-bis [imino-N-methyl-4,2-pyrrolocarbonyl- imino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(
- integralin Mockers refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the oc v ⁇ 3 integrin, to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the ⁇ v ⁇ 5 integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the ⁇ v ⁇ 3 integrin and the v ⁇ 5 integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells.
- the term also refers to antagonists of the 0Cv ⁇ 6 > ⁇ v 8 > ⁇ i ⁇ i, 0C2 ⁇ l> 0C5 ⁇ l > g ⁇ i and oc ⁇ -i integrins.
- the term also refers to antagonists of any combination of
- tyrosine kinase inhibitors include N- (trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, 3-[(2,4-dimethylpyrrol-5- yl)methylidenyl)indolin-2-one, 17-(allylamino)- 17-demethoxygeldanamycin, 4-(3- chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, BIBX1382, 2,3,9,10,1 l,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy- lH-diindolo[l,2,3-fg:3',2',l'-kl]pyrrolo[3,
- the instant compounds are also useful, alone or in combination with platelet fibrinogen receptor (GP Ilb/IIIa) antagonists, such as tirofiban, to inhibit metastasis of cancerous cells.
- Tumor cells can activate platelets largely via thrombin generation. This activation is associated with the release of VEGF.
- the release of VEGF enhances metastasis by increasing extravasation at points of adhesion to vascular endothelium (Amirkhosravi, Platelets 10, 285-292, 1999). Therefore, the present compounds can serve to inhibit metastasis, alone or in combination with GP ⁇ b/HIa) antagonists.
- fibrinogen receptor antagonists examples include abciximab, eptifibatide, sibrafiban, lamifiban, lotrafiban, cromofiban, and CT50352. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.
- administration means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment.
- a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.)
- administration and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- treating cancer refers to administration to a mammal afflicted with a cancerous condition and refers to an effect that alleviates the cancerous condition by killing the cancerous cells, but also to an effect that results in the inhibition of growth and/or metastasis of the cancer.
- the present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents.
- Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's bloodstream by local bolus injection.
- the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
- a suitable amount of compound is administered to a mammal undergoing treatment for cancer.
- Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
- VEGF receptor kinase activity is measured by incorporation of radio-labeled phosphate into polyglutamic acid, tyrosine, 4:1 (pEY) substrate.
- the phosphorylated pEY product is trapped onto a filter membrane and the incorporation of radio-labeled phosphate quantified by scintillation counting.
- the intracellular tyrosine kinase domains of human KDR (Terman, B.I. et al. Oncogene (1991) vol. 6, pp. 1677-1683.) and Flt-1 (Shibuya, M. et al. Oncogene (1990) vol. 5, pp. 519-524) were cloned as glutathione S-transferase (GST) gene fusion proteins. This was accomplished by cloning the cytoplasmic domain of the KDR kinase as an in frame fusion at the carboxy terminus of the GST gene.
- GST glutathione S-transferase
- Soluble recombinant GST-kinase domain fusion proteins were expressed in Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen).
- wash buffer 50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.05% triton X-100, 10 % glycerol, 10 mg/mL of each leupeptin, pepstatin and aprotinin and lmM phenylmethylsulfonyl fluoride.
- Enzyme dilution buffer 50 mM Tris, pH 7.4, 0.1 M NaCl, 1 mM DTT, 10 % glycerol, 100 mg/mL BSA.
- Sf21 cells were infected with recombinant virus at a multiplicity of infection of 5 virus particles/ cell and grown at 27°C for 48 hours.
- Human Umbilical Vein Endothelial Cell Mitogenesis Assay Expression of VEGF receptors that mediate mitogenic responses to the growth factor is largely restricted to vascular endothelial cells.
- Human umbilical vein endothelial cells (HUVECs) in culture proliferate in response to VEGF treatment and can be used as an assay system to quantify the effects of KDR kinase inhibitors on VEGF stimulation.
- quiescent HUVEC monolayers are treated with vehicle or test compound 2 hours prior to addition of VEGF or basic fibroblast growth factor (bFGF).
- the mitogenic response to VEGF or bFGF is determined by measuring the incorporation of [3H]thymidine into cellular DNA.
- HUVECs frozen as primary culture isolates are obtained from Clonetics Corp. Cells are maintained in Endothelial Growth Medium (EGM; Clonetics) and are used for mitogenic assays at passages 3-7.
- EGM Endothelial Growth Medium
- NUNCLON 96-well polystyrene tissue culture plates (NUNC #167008). Assay Medium
- HUVEC monolayers maintained in EGM are harvested by trypsinization and plated at a density of 4000 cells per 100 ⁇ L Assay Medium per well in 96-well plates. Cells are growth-arrested for 24 hours at 37°C in a humidified atmosphere containing 5% CO2-
- Growth-arrest medium is replaced by 100 ⁇ L Assay Medium containing either vehicle (0.25% [v/v] DMSO) or the desired final concentration of test compound. All determinations are performed in triplicate. Cells are then incubated at 37°C/5% CO2 for 2 hours to allow test compounds to enter cells. 3. After the 2-hour pretreatment period, cells are stimulated by addition of 10 ⁇ L/well of either Assay Medium, 10X VEGF solution or 10X bFGF solution. Cells are then incubated at 37°C/5% CO2.
- the compounds of formula I are inhibitors of VEGF and thus are useful for the inhibition of angiogenesis, such as in the treatment of ocular disease, e.g., diabetic retinopathy and in the treatment of cancers, e.g., solid tumors.
- the instant compounds inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 - 5.0 ⁇ M.
- These compounds also show selectivity over related tyrosine kinases (e.g., FGFRl and the Src family; for relationship between Src kinases and VEGFR kinases, see Eliceiri et al., Molecular Cell, Vol. 4, pp.915-924, December 1999).
- Step 1 Synthesis of 2-chloro-3-iodo-quinoline (Intermediate A) A suspension of 3-(2-chloro)-quinolineboronic acid (5.05 g, 24.3 mmol, 1 equiv, prepared by the method of Marsais, F; Godard, A.; Queguiner, G. J. Heterocyclic Chem. 1989, 26, 1589-1594) and N-iodosuccinimide (5.48 g, 24.4 mmol, 1.00 equiv) in acetonitrile (300 mL) was stirred at 23°C in the dark for 20 hours.
- 3-(2-chloro)-quinolineboronic acid 5.05 g, 24.3 mmol, 1 equiv, prepared by the method of Marsais, F; Godard, A.; Queguiner, G. J. Heterocyclic Chem. 1989, 26, 1589-1594
- N-iodosuccinimide 5.48 g, 24.4 mmol
- Step 1 A solution of tert-butyllithium in pentane (1.7 M, 3.95 mL, 6.72 mmol, 1.20 equiv) was added to a solution of intermediate B (1.39 g, 5.60 mmol, 1 equiv) in THE (70 mL) at -78°C. The orange solution was stirred for 15 min, then a solution of trimethyltin chloride (2.23 g, 11.2 mmol, 2.00 equiv) in THF (4.0 mL) was added. The reaction mixture was warmed to 23°C, then partitioned between aqueous pH 7 phosphate buffer and a 1 : 1 mixture of ethyl acetate and hexane (100 mL).
- Step 2 A deoxygenated solution of this residue, intermediate A (0.800 g, 2.76 mmol, 0.500 equiv), tetrakis(triphenylphosphine)palladium (0.160 g, 0.140 mmol, 0.025 equiv), and cuprous iodide (0.053 g, 0.28 mmol, 0.05 equiv) in dioxane (40 mL) was heated at 90°C for 20 hours. The reaction mixture was cooled, then partitioned between brine (150 mL) and ethyl acetate (150 mL). The organic layer was dried over sodium sulfate, then concentrated.
- Step 4 Synthesis of 3-(5-methoxy-lH-pyrrolo[3.2-b1pyridin-2-yl)-lH-quinolin-2-one
- a solution of intermediate C (900 mg, 2.20 mmol) was heated in a 1:1 mixture of acetic acid and water (50 mL) at reflux for 16 hours.
- the reaction mixture was concentrated, and the residue was partitioned between aqueous saturated sodium bicarbonate solution (150 mL) and hot ethyl acetate (3 x 200 mL).
- the combined organic layers were dried over sodium sulfate and concentrated.
- the residue was suspended in ethyl ether (200 mL), filtered, then air-dried to give the titled compound as a yellow solid.
- Examples 2-4 were synthesized in analogous fashion to Example 1 starting from the corresponding azaindoles prepared by the method of Hands, D.; Bishop, B.; Cameron, M.; Edwards, J. S.; Cottrell, I. F.; Wright, S. H. B Synthesis 1996, 887-882.
- reaction mixture was concentrated, and the residue was purified by flash column chromatography (100% hexanes initially, grading to 20% ethyl acetate in hexanes) to afford intermediate E as a colorless oil which solidified upon standing (180 mg, 56%).
- Step 2 Synthesis of 3-(5-methoxy-lH-pyrrolo[2.3-c]pyridin-2-yl)-lH-quinolin-2-one
- Step 1 A solution of tert-butyllithium in pentane (1.7 M, 0.45 mL,
- Step 2 A deoxygenated solution of this solid, intermediate A (150 mg, 0.51 mmol, 1.0 equiv), te ⁇ akis(triphenylphosphine)palladium (30 mg, 0.026 mmol, 0.05 equiv), and potassium phosphate (327 mg, 1.54 mmol, 3.00 equiv) in dioxane (15 mL) was heated at reflux for 2P hours. The reaction mixture was cooled,
- IP then partitioned between water (75 mL) and ethyl acetate (2 x 75 mL). The organic layer was dried over sodium sulfate, then concentrated. The residue was passed through a column of flash-grade silica gel (4P% EtOAc in hexanes initially, grading tolPP% EtOAc). The fractions containing primarily the desired coupled product were concentrated.
- Step 3 A solution of this residue in a 1 : 1 mixture of acetic acid and water was heated at reflux for 2P hours. The reaction mixture was concentrated, and the residue was purified by reverse-phase column chromatography (5% acetonitrile in water initially, grading to 1PP% acetonitrile). The desired fractions were concentrated, and the residue was partitioned between saturated aqueous sodium bicarbonate P solution and ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to afford the titled compound as a yellow solid.
- the titled compound can be made by the reaction of the corresponding methyl ether with HBr according to the procedure in Example 3 above.
- the titled compound can be made via oxidation of the product from Example 3 followed by rearrangement (see Scheme 4).
- Examples 7-9 were synthesized in analogous fashion to Example 1 starting from the corresponding azaindoles prepared by the method of Hands, D.; Bishop, B.; Cameron, M.; Edwards, J. S.; Cottrell, I. F.; Wright, S. H. B Synthesis 1996, 887-882.
- the products can be converted to the N-alkylated compounds of Formula I via the procedure in Scheme 4 followed by alkylation as in Scheme 5, or by other procedures readily available in the chemical literature.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002400923A CA2400923A1 (en) | 2000-02-25 | 2001-02-21 | Tyrosine kinase inhibitors |
JP2001561318A JP2003523390A (en) | 2000-02-25 | 2001-02-21 | Tyrosine kinase inhibitor |
AU39814/01A AU778417B2 (en) | 2000-02-25 | 2001-02-21 | Tyrosine kinase inhibitors |
EP01914424A EP1259236A4 (en) | 2000-02-25 | 2001-02-21 | Tyrosine kinase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18502400P | 2000-02-25 | 2000-02-25 | |
US60/185,024 | 2000-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001062252A1 true WO2001062252A1 (en) | 2001-08-30 |
Family
ID=22679242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/005567 WO2001062252A1 (en) | 2000-02-25 | 2001-02-21 | Tyrosine kinase inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1259236A4 (en) |
JP (1) | JP2003523390A (en) |
AU (1) | AU778417B2 (en) |
CA (1) | CA2400923A1 (en) |
WO (1) | WO2001062252A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035047A2 (en) * | 2001-10-25 | 2003-05-01 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
US6756383B2 (en) | 2000-09-01 | 2004-06-29 | Chiron Corporation | Heterocyclic derivatives of quinolinone benimidazoles |
US6770643B2 (en) | 1999-12-24 | 2004-08-03 | Aventis Pharma Limited | Azaindoles |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
US6831175B2 (en) | 2001-12-13 | 2004-12-14 | Abbott Laboratories | Kinase inhibitors |
US6897207B2 (en) | 2001-06-21 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Azaindoles |
WO2006071035A1 (en) * | 2004-12-31 | 2006-07-06 | Lg Life Sciences, Ltd. | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives |
US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
WO2009114373A1 (en) * | 2008-03-10 | 2009-09-17 | Sanofi-Aventis | Treatment for ocular-related disorders |
EP2301546A1 (en) | 2005-01-27 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Treatment of metastasized tumors |
US8133847B2 (en) | 2006-07-20 | 2012-03-13 | Syngenta Limited | Pyrido[2,3-B]pyrazine derivatives useful as herbicidal compounds |
US8222413B2 (en) | 2005-05-17 | 2012-07-17 | Novartis Ag | Methods for synthesizing heterocyclic compounds |
US8450459B2 (en) | 2003-10-10 | 2013-05-28 | Novo Nordisk A/S | IL-21 derivatives and variants |
WO2014110200A1 (en) | 2013-01-10 | 2014-07-17 | Zisman Lawrence S | Non-selective kinase inhibitors |
EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
WO2015054574A1 (en) | 2013-10-11 | 2015-04-16 | Zisman Lawrence S | Spray dry formulations |
US10231966B2 (en) | 2016-10-27 | 2019-03-19 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007508332A (en) * | 2003-10-17 | 2007-04-05 | ノボ ノルディスク アクティーゼルスカブ | Combination therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409930A (en) * | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420382B2 (en) * | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
-
2001
- 2001-02-21 CA CA002400923A patent/CA2400923A1/en not_active Abandoned
- 2001-02-21 WO PCT/US2001/005567 patent/WO2001062252A1/en active IP Right Grant
- 2001-02-21 JP JP2001561318A patent/JP2003523390A/en not_active Withdrawn
- 2001-02-21 AU AU39814/01A patent/AU778417B2/en not_active Ceased
- 2001-02-21 EP EP01914424A patent/EP1259236A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409930A (en) * | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
Non-Patent Citations (2)
Title |
---|
MENG ET AL.: "A photochemical synthesis of 3-aryl-1-methylquinolinones", J. HETEROCYCLIC CHEM., vol. 28, no. 6, October 1991 (1991-10-01), pages 1481 - 1484, XP002939966 * |
See also references of EP1259236A4 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770643B2 (en) | 1999-12-24 | 2004-08-03 | Aventis Pharma Limited | Azaindoles |
US6756383B2 (en) | 2000-09-01 | 2004-06-29 | Chiron Corporation | Heterocyclic derivatives of quinolinone benimidazoles |
US7368459B2 (en) | 2000-09-01 | 2008-05-06 | Chiron Corporation | Heterocyclic compounds |
US6759417B2 (en) | 2000-09-01 | 2004-07-06 | Chiron Corporation | Heterocyclic compounds |
US7138409B2 (en) | 2000-09-01 | 2006-11-21 | Chiron Corporation | Heterocyclic compounds |
US6762194B2 (en) | 2000-09-11 | 2004-07-13 | Chiron Corporation | Quinolinone derivatives |
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
US6774237B2 (en) | 2000-09-11 | 2004-08-10 | Chiron Corporation | Quinolinone derivatives |
US7335774B2 (en) | 2000-09-11 | 2008-02-26 | Novartis Vaccines And Diagnostics, Inc. | Quinolinone derivatives |
US6800760B2 (en) | 2000-09-11 | 2004-10-05 | Chiron Corporation | Quinolinone derivatives |
US7598268B2 (en) | 2000-09-11 | 2009-10-06 | Novartis Vaccines & Diagnostics, Inc. | Quinolinone derivatives |
US6897207B2 (en) | 2001-06-21 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Azaindoles |
US7943616B2 (en) | 2001-06-21 | 2011-05-17 | Aventis Pharmaceuticals Inc. | Azaindoles for inhibiting aurora2 and other kinases |
JP2005506366A (en) * | 2001-10-25 | 2005-03-03 | ノバルティス アクチエンゲゼルシャフト | Combination comprising a selective cyclooxygenase-2 inhibitor |
WO2003035047A3 (en) * | 2001-10-25 | 2003-10-23 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
WO2003035047A2 (en) * | 2001-10-25 | 2003-05-01 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
US6831175B2 (en) | 2001-12-13 | 2004-12-14 | Abbott Laboratories | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
EP2573079A2 (en) | 2002-08-23 | 2013-03-27 | Novartis Vaccines and Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
US8450459B2 (en) | 2003-10-10 | 2013-05-28 | Novo Nordisk A/S | IL-21 derivatives and variants |
EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
WO2006071035A1 (en) * | 2004-12-31 | 2006-07-06 | Lg Life Sciences, Ltd. | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives |
EP2301546A1 (en) | 2005-01-27 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Treatment of metastasized tumors |
US8222413B2 (en) | 2005-05-17 | 2012-07-17 | Novartis Ag | Methods for synthesizing heterocyclic compounds |
US8133847B2 (en) | 2006-07-20 | 2012-03-13 | Syngenta Limited | Pyrido[2,3-B]pyrazine derivatives useful as herbicidal compounds |
WO2009114373A1 (en) * | 2008-03-10 | 2009-09-17 | Sanofi-Aventis | Treatment for ocular-related disorders |
WO2014110200A1 (en) | 2013-01-10 | 2014-07-17 | Zisman Lawrence S | Non-selective kinase inhibitors |
US9815815B2 (en) | 2013-01-10 | 2017-11-14 | Pulmokine, Inc. | Non-selective kinase inhibitors |
US10246438B2 (en) | 2013-01-10 | 2019-04-02 | Pulmokine, Inc | Non-selective kinase inhibitors |
US10532994B2 (en) | 2013-01-10 | 2020-01-14 | Pulmokine, Inc. | Non-selective kinase inhibitors |
WO2015054574A1 (en) | 2013-10-11 | 2015-04-16 | Zisman Lawrence S | Spray dry formulations |
US9925184B2 (en) | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
US10231966B2 (en) | 2016-10-27 | 2019-03-19 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
US11364238B2 (en) | 2016-10-27 | 2022-06-21 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
Also Published As
Publication number | Publication date |
---|---|
EP1259236A1 (en) | 2002-11-27 |
CA2400923A1 (en) | 2001-08-30 |
JP2003523390A (en) | 2003-08-05 |
EP1259236A4 (en) | 2004-11-03 |
AU3981401A (en) | 2001-09-03 |
AU778417B2 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1259235B1 (en) | Tyrosine kinase inhibitors | |
US6313138B1 (en) | Tyrosine kinase inhibitors | |
US6958340B2 (en) | Tyrosine kinase inhibitors | |
US6927293B2 (en) | Tyrosine kinase inhibitors | |
US6544988B1 (en) | Tyrosine kinase inhibitors | |
US7109204B2 (en) | Tyrosine kinase inhibitors | |
EP1226119B1 (en) | Tyrosine kinase inhibitors | |
US20040171630A1 (en) | Tyrosine kinase inhibitors | |
US20040235867A1 (en) | Tyrosine kinase inhibitors | |
US20030100567A1 (en) | Tyrosine kinase inhibitors | |
AU2001238575A1 (en) | Tyrosine kinase inhibitors | |
US20040220216A1 (en) | Tyrosine kinase inhibitors | |
WO2003024969A1 (en) | Tyrosine kinase inhibitors | |
WO2001029025A2 (en) | Tyrosine kinase inhibitors | |
AU2002346053A1 (en) | Tyrosine kinase inhibitors | |
WO2003024931A1 (en) | Tyrosine kinase inhibitors | |
AU778417B2 (en) | Tyrosine kinase inhibitors | |
US20040181066A1 (en) | Tyrosine kinase inhibitors | |
WO2003015717A2 (en) | Tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 39814/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001914424 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 561318 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2400923 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001914424 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 39814/01 Country of ref document: AU |